Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective (Q83940125)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

N Schub

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

A Günther

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

A Schrauder

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

C Ehlert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

M Gramatzki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

R Repp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

29 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

143-147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20348971%20AND%20SRC:MED&resulttype=core&format=json

Current and novel therapies in acute GVHD.

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

Successful use of Campath-1H in the treatment of steroid refractory liver GvHD.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021

Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.68

7 January 2021